People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Incline Therapeutics, Inc. | — | Biotechnology | Series B | $43.9M | $853.3M | 2009 |
| Recida Therapeutics, Inc. | — | Biotechnology | Series A | $5.7M | $204.9M | 2018 |
| Nexcida Therapeutics, Inc. | — | Other | Seed | $2.8M | $51.1M | 2015 |
David Socks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Socks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Heron | 2 | 11 |
| Yigong Ge | 2 | 2 |
| James Topper | 1 | 12 |
| Brent Ahrens | 1 | 7 |
| Chen Yu | 1 | 7 |
| Terry Gould | 1 | 6 |
| Theodore R. Schroeder | 1 | 4 |
| Jim Young | 1 | 4 |
| Jim Glasheen | 1 | 3 |
| Michael Savino | 1 | 3 |
| Alan Levy, Ph.D. | 1 | 3 |
| David A Socks | 1 | 2 |
| James Topper, M.D., Ph.D. | 1 | 1 |
| James W. Young, Ph.D. | 1 | 1 |
| James Glasheen, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.